The clinical case of the first high risk percutaneus coronary intervention under use of the PulseCath iVAC 2L left ventricular assist device in Russia
https://doi.org/10.17802/2306-1278-2020-9-1-103-109
Abstract
Percutaneous left ventricular assist devices are necessary to maintain blood circulation in patients with cardiogenic shock after high risk percutaneous coronary interventions. The PulseCath iVAC 2L is a new device that can be implanted percutaneously via the femoral artery. The device consists of an extracorporeal membrane pump and a catheter, which is inserted into the left ventricle through the aorta. The pump is connected to the console of the intra-aortic balloon counterpulsator generating a pulsatile blood flow.
About the Authors
B. G. Alekyan
A.V. Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Alekyan Bagrat G.-PhD, Professor, Academician of RAS; Deputy Director of the A.V. Vishnevsky National Medical Research Center of Surgery.
27, Bol'shaya Serpukhovskaya St., Moscow, Russian Federation, 117997
N. G Karapetyan
A.V. Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Karapetyan Narek G.- PhD, senior researcher at the Endovascular Surgery Center, A.V. Vishnevsky National Medical Research Center of Surgery.
27, Bol'shaya Serpukhovskaya St., Moscow, Russian Federation, 117997
A. Ya. Novak
A.V. Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Novak Alexander Ya.-physician at the Endovascular Surgery Center, A.V. Vishnevsky National Medical Research Center of Surgery.
27, Bol'shaya Serpukhovskaya St., Moscow, Russian Federation, 117997
G. P. Plotnikov
A.V. Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Plotnikov Georgiy P.- PhD, Head of the ICU, A.V. Vishnevsky National Medical Research Center of Surgery.
27, Bol'shaya Serpukhovskaya St., Moscow, Russian Federation, 117997
Yu. B. Knysh
A.V. Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Knysh Yulia B.- cardiologist at the Endovascular Surgery Center, A.V. Vishnevsky National Medical Research Center of Surgery.
27, Bol'shaya Serpukhovskaya St., Moscow, Russian Federation, 117997
G. S. Grigoryan
A.V. Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Grigoryan Grigor S.-resident physician at the Endovascular Surgery Center, A.V. Vishnevsky National Medical Research Center of Surgery.
27, Bol'shaya Serpukhovskaya St., Moscow, Russian Federation, 117997
References
1. Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson, Fernando Alfonso, Adrian P Banning, Umberto Benedetto, Robert A Byrne, Jean-Philippe Collet, Volkmar Falk, Stuart J Head, Peter Jüni, Adnan Kastrati, Akos Koller, Steen D Kristensen, Josef Niebauer, Dimitrios J Richter, Petar M Seferović, Dirk Sibbing, Giulio G Stefanini, Stephan Windecker, Rashmi Yadav, Michael O Zembala, ESC Scientific Document Group; 2018 ESC/EACTS Guidelines on myocardial revascularization, European Heart Journal, Volume 40, Issue 2, 7 January 2019, Pages 87–165, https://doi.org/10.1093/eurheartj/ehy394
2. Alekyan B.G., Grigor'yan A.M., Staferov A.V., Karapetyan N.G. Endovascular diagnostics and treatment in the Russian Federation (2017). Endovaskulyarnaya Khirurgiya (Russian Journal of Endovascular Surgery). 2018; 2 (5): 93–240. (In Russan) doi: 10.24183/2409-4080-2018-5-2-93-240
3. Kapur N.K., Esposito M. Hemodynamic support with percutaneous devices in patients with heart failure. Heart Failure Clinics. 2015;11(2):215-230. doi: 10.1016/j.hfc.2014.12.012
4. Thiele H., Zeymer U., Neumann F.J., Ferenc M., Olbrich H.G., Hausleiter J., et al. Intraaortic balloon counterpulsation inacute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 382(9905),1638–1645 (2013). doi: 10.1016/S0140-6736(13)61783-3
5. Bugaenko D.V., Fominykh M.V., Eremenko A.A. Current percutaneous left ventricular assist devices. Kardiologia i serdeсnososudistaа hirurgia. 2018;11(3):35-40. https://doi.org/10.17116/ kardio201811335
6. Burkhoff D., Cohen H., Brunckhorst C., O’neill W.W., TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the Tandem Heart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152(3):469-e1. doi: 10.1016/j.ahj.2006.05.031
7. Gilotra N.A., Stevens G.R. Temporary mechanical circulatory sup-port: a review of the options, indications, and outcomes. Clinical Medicine Insights Cardiology. 2014;8(Suppl 1):75. doi: 10.4137/CMC.S15718
8. Thiele H., Lauer B., Hambrecht R., Boudriot E., Cohen H.A., Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation. 2001;104(24):2917-2922. doi: 10.1161/hc4901.100361
9. Thiele H., Sick P., Boudriot E., Diederich K.-W., Hambrecht R., Niebauer J., Schuler G. Randomized comparison of intraaortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. European Heart Journal. 2005;26(13):1276-1283. doi:10.1093/eurheartj/ehi161
10. Sauren L.D., Accord R.E., Hamzeh K., De Jong M., Van Der Na-gel T., Van Der Veen F.H., Maessen J.G. Combined Impella and Intra-aortic Balloon Pump Support to Improve Both Ventricular Unloading and Coronary Blood Flow for Myocardial Recovery: An Experimental Study. Artificial Organs. 2007;31(11):839-842. doi:10.1111/j.1525-1594.2007.00477.x
11. Sjauw K.D., Konorza T., Erbel R., Danna P.L., Viecca M., Min-den H.-H., Butter C., Engstrøm T., Hassager C., Machado F.P., et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device: the Europella registry. J Am Coll Cardiol. 2009;54(25):2430-2434. DOI: 10.1016/j.jacc.2009.09.018
12. Maini B., Naidu S.S., Mulukutla S., Kleiman N., Schreiber T., Wohns D., Dixon S., Rihal C., Dave R., O’neill W. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: The USpella Registry. Catheter Cardiovasc Interv. 2012;80(5):717-725. doi:10.1016/j.jacc.2009.09.018
13. Samol A., Schmidt S., Zeyes M., Dürrwald S., Wiemer M. First high-risk percutaneous coronary intervention under use of the iVAC2l system in Germany. Future Cardiol. 2017;13(2):117-123. doi: 10.2217/fca-2016-00644
14. Mariani M.A., Diephuis J.C., Kuipers M.J., Gianoli M., Grandjean J.G. Off-pump coronary artery bypass graft surgery with a pulsatile catheter pump for left ventricular dysfunction. Ann Thorac Surg. 2007;84(2):690-692. doi:10.1016/j.athoracsur.2006.12.016
15. den Uil C.A., Daemen J., Lenzen M.J., Maugenest A.M., Joziasse L., van Geuns R.J., Van Mieghem N.M. Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. EuroIntervention. 2017;12(14):1689-1696. doi:10.4244/ EIJ-D-16-00371
16. Cheng A, Williamitis CA, Slaughter MS. Comparison of continuous-flow and pulsatile-flow left ventricular assist devices: is there an advantage to pulsatility? Ann Cardiothorac Surg
Review
For citations:
Alekyan B.G., Karapetyan N.G., Novak A.Ya., Plotnikov G.P., Knysh Yu.B., Grigoryan G.S. The clinical case of the first high risk percutaneus coronary intervention under use of the PulseCath iVAC 2L left ventricular assist device in Russia. Complex Issues of Cardiovascular Diseases. 2020;9(1):103-109. (In Russ.) https://doi.org/10.17802/2306-1278-2020-9-1-103-109
Views:
1564
